Riess on the FAVOUR Trial Furmonertinib in EGFR Exon20Ins Mut+ NSCLC
December 27th 2023Jonathan W. Riess, MD, medical director of thoracic oncology, University of California, Davis Comprehensive Cancer Center, discusses the phase 1b FAVOUR trial of furmonertinib in patients with advanced non–small cell lung cancer harboring EGFR Exon20 insertion mutations.